Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × bafetinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Genitourinary 1

Conditions

Hormone Refractory Prostate Cancer 1

Interventions

Docetaxel 177 Prednisone 132 Gemcitabine 132 pembrolizumab 109 enzalutamide 104 Abiraterone Acetate 97 Nivolumab 93 Magnetic Resonance Spectroscopy 93 Cisplatin 89 Radiotherapy 86 Leuprolide 85 Sunitinib 80 Carboplatin 75 Specimen Handling 64 Radiosurgery 59 Paclitaxel 57 Androgen Antagonists 56 Goserelin 55 Ipilimumab 52 bicalutamide 51 apalutamide 50 Sorafenib 48 Bevacizumab 47 cabozantinib 45 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45 Everolimus 42 cabazitaxel 41 abiraterone 41 durvalumab 38 atezolizumab 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01215799 2011-12-15

PROACT

CytRx

Phase 2 Completed

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡